Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis
Thymopentin (TP5), a clinically used immunomodulatory pentapeptide, can efficiently promote thymocyte differentiation and influence mature T-cell function, thus playing an essential role in the cancer immunotherapy. However, the excellent water solubility and high IC50 of TP5 result in an uncontroll...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006423001059 |
| _version_ | 1797796412103065600 |
|---|---|
| author | Ning Ding Kai He Hailong Tian Lei Li Qiong Li Shuaijun Lu Ke Ding Jiaqi Liu Edouard C. Nice Wei Zhang Canhua Huang Yong Tang Zhisen Shen |
| author_facet | Ning Ding Kai He Hailong Tian Lei Li Qiong Li Shuaijun Lu Ke Ding Jiaqi Liu Edouard C. Nice Wei Zhang Canhua Huang Yong Tang Zhisen Shen |
| author_sort | Ning Ding |
| collection | DOAJ |
| description | Thymopentin (TP5), a clinically used immunomodulatory pentapeptide, can efficiently promote thymocyte differentiation and influence mature T-cell function, thus playing an essential role in the cancer immunotherapy. However, the excellent water solubility and high IC50 of TP5 result in an uncontrolled release behavior, requiring a high loading efficiency to achieve high dosage. Here in, we reported that TP5, combined with specific chemotherapeutic agents, can co-assemble into nanogels due to multiple hydrogen bonding sites. The co-assembly of TP5 with chemotherapeutic agent doxorubicin (DOX) into a carrier-free and injectable chemo-immunotherapy nanogel can enhance the cancer immunity cycle against melanoma metastasis. In this study, the designed nanogel guarantees high drug loading of TP5 and DOX and ensures a site-specific and controlled release of TP5 and DOX with minimal side effects, thus addressing the bottlenecks encountered by current chemo-immunotherapy. Moreover, the released DOX can effectively induce tumor cell apoptosis and immunogenic cell death (ICD) to activate immune initiation. Meanwhile, TP5 can significantly promote the proliferation and differentiation of dendritic cells (DCs) and T lymphocytes to amplify the cancer immunity cycle. As a result, this nanogel shows excellent immunotherapeutic efficacy against melanoma metastasis, as well as an effective strategy for TP5 and DOX application. |
| first_indexed | 2024-03-13T03:32:42Z |
| format | Article |
| id | doaj.art-a3fdea32c58840bfa155114c0dfdf499 |
| institution | Directory Open Access Journal |
| issn | 2590-0064 |
| language | English |
| last_indexed | 2024-03-13T03:32:42Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj.art-a3fdea32c58840bfa155114c0dfdf4992023-06-24T05:18:38ZengElsevierMaterials Today Bio2590-00642023-06-0120100645Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasisNing Ding0Kai He1Hailong Tian2Lei Li3Qiong Li4Shuaijun Lu5Ke Ding6Jiaqi Liu7Edouard C. Nice8Wei Zhang9Canhua Huang10Yong Tang11Zhisen Shen12School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR ChinaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, ChinaNingbo Hospital of Ningbo University 247 Renmin Road, Jiangbei District Ningbo, Zhejiang, 315020, ChinaClinical Genetics Laboratory, Affiliated Hospital, Chengdu University, Chengdu 610081, ChinaInternational School of Public Health and Whole Health, Hainan Medical University, Haikou, 571199, PR ChinaDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, 3800, AustraliaDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR China; Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China; Corresponding author.School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, PR ChinaRehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China; Corresponding author.Department of Otorhinolaryngology and Head and Neck Surgery, The Affiliated Lihuili Hospital, Ningbo University, 315040 Ningbo, Zhejiang, China; Corresponding author.Thymopentin (TP5), a clinically used immunomodulatory pentapeptide, can efficiently promote thymocyte differentiation and influence mature T-cell function, thus playing an essential role in the cancer immunotherapy. However, the excellent water solubility and high IC50 of TP5 result in an uncontrolled release behavior, requiring a high loading efficiency to achieve high dosage. Here in, we reported that TP5, combined with specific chemotherapeutic agents, can co-assemble into nanogels due to multiple hydrogen bonding sites. The co-assembly of TP5 with chemotherapeutic agent doxorubicin (DOX) into a carrier-free and injectable chemo-immunotherapy nanogel can enhance the cancer immunity cycle against melanoma metastasis. In this study, the designed nanogel guarantees high drug loading of TP5 and DOX and ensures a site-specific and controlled release of TP5 and DOX with minimal side effects, thus addressing the bottlenecks encountered by current chemo-immunotherapy. Moreover, the released DOX can effectively induce tumor cell apoptosis and immunogenic cell death (ICD) to activate immune initiation. Meanwhile, TP5 can significantly promote the proliferation and differentiation of dendritic cells (DCs) and T lymphocytes to amplify the cancer immunity cycle. As a result, this nanogel shows excellent immunotherapeutic efficacy against melanoma metastasis, as well as an effective strategy for TP5 and DOX application.http://www.sciencedirect.com/science/article/pii/S2590006423001059ThymopentinNanogelCancer immunity cycleImmunogenic cell deathChemo-immunotherapyMelanoma metastasis |
| spellingShingle | Ning Ding Kai He Hailong Tian Lei Li Qiong Li Shuaijun Lu Ke Ding Jiaqi Liu Edouard C. Nice Wei Zhang Canhua Huang Yong Tang Zhisen Shen Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis Materials Today Bio Thymopentin Nanogel Cancer immunity cycle Immunogenic cell death Chemo-immunotherapy Melanoma metastasis |
| title | Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| title_full | Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| title_fullStr | Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| title_full_unstemmed | Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| title_short | Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| title_sort | carrier free delivery of thymopentin regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis |
| topic | Thymopentin Nanogel Cancer immunity cycle Immunogenic cell death Chemo-immunotherapy Melanoma metastasis |
| url | http://www.sciencedirect.com/science/article/pii/S2590006423001059 |
| work_keys_str_mv | AT ningding carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT kaihe carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT hailongtian carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT leili carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT qiongli carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT shuaijunlu carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT keding carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT jiaqiliu carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT edouardcnice carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT weizhang carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT canhuahuang carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT yongtang carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis AT zhisenshen carrierfreedeliveryofthymopentinregulatedinjectablenanogelsviaanenhancedcancerimmunitycycleagainstmelanomametastasis |